Live Breaking News & Updates on போர்டபல் மீயொலி சிகிச்சை சாதனங்கள்

Stay updated with breaking news from போர்டபல் மீயொலி சிகிச்சை சாதனங்கள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

NanoVibronix Announces Expanded CMS Reimbursement Approval for PainShield


(NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded its reimbursement approval of the company’s PainShield™ product by adding the device to its Durable Medical Equipment (DME) schedule.
Effective immediately, PainShield is reimbursable as an approved medical device under a unique reimbursement code assigned by CMS for low frequency ultrasonic diathermy treatment specifically for home use. The product is currently the only device approved for reimbursement under the unique HCPCS code K1004, which was established through the company’s efforts and work with CMS. Visit ....

Brian Murphy , Us Centers For Medicare , Medicaid Services , Nanovibronix Inc , Surface Acoustic Wave , Portable Ultrasonic Therapeutic Devices , Durable Medical Equipment , Nasdaq Naov , Nanovibronix Inc , பிரையன் மர்பி , எங்களுக்கு மையங்கள் க்கு மருத்துவ , மருத்துவ உதவி சேவைகள் , மேற்பரப்பு ஒலி அலை , போர்டபல் மீயொலி சிகிச்சை சாதனங்கள் , நீடித்த மருத்துவ உபகரணங்கள் ,

NanoVibronix Announces Start of Real World Patient Study of UroShield


., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that an independent, real world patient study of its UroShield has commenced at Southampton University Health Sciences in partnership with Southern Health NHS Foundation Trust, an NHS health service provider of community services in the United Kingdom.
“This is another step forward in our efforts towards NHS fully adopting UroShield as a unique preventative device,” stated Brian Murphy, CEO of NanoVibronix. “We are eager to receive the results of this independent study as there are an estimated 100,000 patients living in community settings in the U.K. who are reliant on indwelling catheters and at risk of developing a catheter-associated urinary tract infection (CAUTI). There are also an additional 154,000 patients hospitalized annually who are catheterized for more than 48 hours and ....

New York , United States , H Efa , United Kingdom , Brian Murphy , Exchange Commission , Company Annual Report On Form , Southern Health , Southampton University Health Sciences , Nanovibronix Inc , Surface Acoustic Wave , Portable Ultrasonic Therapeutic Devices , Annual Report , Quarterly Reports , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஏச் எபா , ஒன்றுபட்டது கிஂக்டம் , பிரையன் மர்பி , பரிமாற்றம் தரகு , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , தெற்கு ஆரோக்கியம் , மேற்பரப்பு ஒலி அலை , போர்டபல் மீயொலி சிகிச்சை சாதனங்கள் , ஆண்டு அறிக்கை , காலாண்டு அறிக்கைகள் ,